DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation.
Our previous observation of a higher incidence of FLT3-ITD in DR(-) M1/M2 AML than in DR(+) M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR(-) AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR(-) cases, but not in any of 28 DR(+) cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.
Syampurnawati
Meilani
M
International Center for Medical Research and Treatment (ICMRT), Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan.
Tatsumi
Eiji
E
Ardianto
Bambang
B
Takenokuchi
Mariko
M
Nakamachi
Yuji
Y
Kawano
Seiji
S
Kumagai
Shun-ichi
S
Saigo
Katsuyasu
K
Matsui
Toshimitsu
T
Takahashi
Takayuki
T
Nagai
Ken-ichi
K
Gunadi
Nishio
Hisahide
H
Yabe
Hiroki
H
Kondo
Shin-Ichi
S
Hayashi
Yoshitake
Y
D001483:Base Sequence; D018076:DNA, Complementary; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology; D000090243:Nucleophosmin; D020133:Reverse Transcriptase Polymerase Chain Reaction
D018076:DNA, Complementary; D006684:HLA-DR Antigens; C000716967:NPM1 protein, human; D000090243:Nucleophosmin